- 2025 cash burn is expected to be approximately $150 million with full-year GAAP operating expenses around $230 million.
- Cash, cash equivalents, and investments totaled $302.6 million as of June 30, 2025.
- Cash runway extends into the second half of 2027, supporting ongoing operations and clinical trials.
- Financial guidance excludes any impact from potential business development activities.
- G&A expenses for Q2 2025 were $14.3 million, including $6.1 million in noncash stock-based compensation.
- Net loss for Q2 2025 was $50.9 million or $0.23 per share, including $8.7 million noncash stock-based compensation and $2.4 million impairment charges.
- R&D expenses for Q2 2025 were $40.2 million, including $2.6 million in noncash stock-based compensation.
Related items and other data are not available for this feed item.
Dafinchi